These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 19238094

  • 1. Combination treatment with octreotide, midodrine, and albumin improves survival in patients with type 1 and type 2 hepatorenal syndrome.
    Skagen C, Einstein M, Lucey MR, Said A.
    J Clin Gastroenterol; 2009 Aug; 43(7):680-5. PubMed ID: 19238094
    [Abstract] [Full Text] [Related]

  • 2. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F, Pantea L, Sniderman K.
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [Abstract] [Full Text] [Related]

  • 3. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
    Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, Amodio P, Sticca A, Caregaro L, Maffei-Faccioli A, Gatta A.
    Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
    [Abstract] [Full Text] [Related]

  • 4. Liver transplant outcomes for patients with hepatorenal syndrome treated with pretransplant vasoconstrictors and albumin.
    Rice JP, Skagen C, Said A.
    Transplantation; 2011 May 27; 91(10):1141-7. PubMed ID: 21544034
    [Abstract] [Full Text] [Related]

  • 5. The effects of chronic treatment with octreotide versus octreotide plus midodrine on systemic hemodynamics and renal hemodynamics and function in nonazotemic cirrhotic patients with ascites.
    Kalambokis G, Economou M, Fotopoulos A, Al Bokharhii J, Pappas C, Katsaraki A, Tsianos EV.
    Am J Gastroenterol; 2005 Apr 27; 100(4):879-85. PubMed ID: 15784036
    [Abstract] [Full Text] [Related]

  • 6. Terlipressin and albumin combination treatment in hepatorenal syndrome.
    Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A.
    Hepatogastroenterology; 2003 Dec 27; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
    [Abstract] [Full Text] [Related]

  • 7. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.
    Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, Mason AL, Gutfreund K, Bain VG.
    Liver Int; 2009 Feb 27; 29(2):169-74. PubMed ID: 18492024
    [Abstract] [Full Text] [Related]

  • 8. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
    Karwa R, Woodis CB.
    Ann Pharmacother; 2009 Apr 27; 43(4):692-9. PubMed ID: 19299324
    [Abstract] [Full Text] [Related]

  • 9. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
    Moreau R, Lebrec D.
    Hepatology; 2006 Mar 27; 43(3):385-94. PubMed ID: 16496352
    [Abstract] [Full Text] [Related]

  • 10. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M, Pépin MN, Guevara M, Díaz F, Torre A, Monescillo A, Soriano G, Terra C, Fábrega E, Arroyo V, Rodés J, Ginès P, TAHRS Investigators.
    Gastroenterology; 2008 May 27; 134(5):1352-9. PubMed ID: 18471512
    [Abstract] [Full Text] [Related]

  • 11. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study.
    Kiser TH, Fish DN, Obritsch MD, Jung R, MacLaren R, Parikh CR.
    Nephrol Dial Transplant; 2005 Sep 27; 20(9):1813-20. PubMed ID: 15956066
    [Abstract] [Full Text] [Related]

  • 12. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
    Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P, Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome.
    Hepatology; 2015 Aug 27; 62(2):567-74. PubMed ID: 25644760
    [Abstract] [Full Text] [Related]

  • 13. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P, Volpin R, Piovan D, Bortoluzzi A, Craighero R, Bottaro S, Finucci GF, Casiglia E, Sticca A, De Toni R, Pavan L, Gatta A.
    Hepatology; 1998 Oct 27; 28(4):937-43. PubMed ID: 9755229
    [Abstract] [Full Text] [Related]

  • 14. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.
    Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi A, Fagiuoli S, Spadaccini A, Trotta E, Laffi G, Koch M, Riggio O, Boccia S, Felder M, Balzani S, Bruno S, Angeli P, Italian Association of the Hospital Gastroenterologists (AIGO) investigators.
    J Hepatol; 2011 Dec 27; 55(6):1241-8. PubMed ID: 21703199
    [Abstract] [Full Text] [Related]

  • 15. Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.
    Esrailian E, Pantangco ER, Kyulo NL, Hu KQ, Runyon BA.
    Dig Dis Sci; 2007 Mar 27; 52(3):742-8. PubMed ID: 17235705
    [Abstract] [Full Text] [Related]

  • 16. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: a case-control study.
    Alessandria C, Debernardi-Venon W, Carello M, Ceretto S, Rizzetto M, Marzano A.
    Dig Liver Dis; 2009 Apr 27; 41(4):298-302. PubMed ID: 19158001
    [Abstract] [Full Text] [Related]

  • 17. [Vasoconstrictors in the treatment of hepatorenal syndrome].
    Ortega R, Calahorra B, Ginès P.
    Nefrologia; 2002 Apr 27; 22 Suppl 5():56-61. PubMed ID: 12107919
    [No Abstract] [Full Text] [Related]

  • 18. The management of hepatorenal syndrome.
    Carl DE, Sanyal A.
    Minerva Gastroenterol Dietol; 2009 Jun 27; 55(2):207-26. PubMed ID: 19305378
    [Abstract] [Full Text] [Related]

  • 19. Long-term outcome of patients treated with terlipressin for types 1 and 2 hepatorenal syndrome.
    Testro AG, Wongseelashote S, Angus PW, Gow PJ.
    J Gastroenterol Hepatol; 2008 Oct 27; 23(10):1535-40. PubMed ID: 17784863
    [Abstract] [Full Text] [Related]

  • 20. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
    Ortega R, Ginès P, Uriz J, Cárdenas A, Calahorra B, De Las Heras D, Guevara M, Bataller R, Jiménez W, Arroyo V, Rodés J.
    Hepatology; 2002 Oct 27; 36(4 Pt 1):941-8. PubMed ID: 12297842
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.